Association of sustained high plasma trough concentration of voriconazole with the incidence of hepatotoxicity

Clinica Chimica Acta

Volumn 424, Issue , 2013, Pages 119-122

  Suzuki, Yosuke ^a   Tokimatsu, Issei ^b   Sato, Yuhki ^a   Kawasaki, Kanako ^a   Sato, Yukie ^a   Goto, Tomomi ^a   Hashinaga, Kazuhiko ^b   Itoh, Hiroki ^a   Hiramatsu, Kazufumi ^b   Kadota, Jun Ichi ^b  

^a OITA UNIVERSITY HOSPITAL   (Japan)

^b OITA UNIVERSITY   (Japan)

Author keywords

Hepatotoxicity; Pharmacokinetics; TDM; Therapeutic drug monitoring; Trough; Voriconazole

Indexed keywords

VORICONAZOLE;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MONITORING; DRUG SAFETY; FEMALE; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; INCIDENCE; JAPANESE; LIVER TOXICITY; MALE; PATIENT CODING; PRIORITY JOURNAL; SCHOOL CHILD;

HEPATOTOXICITY; PHARMACOKINETICS; TDM; THERAPEUTIC DRUG MONITORING; TROUGH; VORICONAZOLE;

ADOLESCENT; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; CHILD; DRUG DOSAGE CALCULATIONS; DRUG MONITORING; FEMALE; HUMANS; LIVER; LIVER FUNCTION TESTS; LOGISTIC MODELS; MALE; MIDDLE AGED; MYCOSES; PYRIMIDINES; TREATMENT OUTCOME; TRIAZOLES;

EID: 84879563254     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2013.05.025     Document Type: Article

References (15)

1. Walsh T.J., Anaissie E.J., Denning D.W., et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008, 46:327-360.
2. Lortholary O., Obenga G., Biswas P., et al. International retrospective analysis of 73 cases of invasive fusariosis treated with voriconazole. Antimicrob Agents Chemother 2010, 54:4446-4450.
3. Boyd A.E., Modi S., Howard S.J., Moore C.B., Keevil B.G., Denning D.W. Adverse reactions to voriconazole. Clin Infect Dis 2004, 39:1241-1244.
4. Theuretzbacher U., Ihle F., Derendorf H. Pharmacokinetic/pharmacodynamic profile of voriconazole. Clin Pharmacokinet 2006, 45:649-663.
5. Weiss J., Ten Hoevel M.M., Burhenne J., et al. CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole. J Clin Pharmacol 2009, 49:196-204.
6. Dolton M.J., Ray J.E., Chen S.C., Ng K., Pont L.G., McLachlan A.J. Multicenter study of voriconazole pharmacokinetics and therapeutic drug monitoring. Antimicrob Agents Chemother 2012, 56:4793-4799.
7. Mitsani D., Nguyen M.H., Shields R.K., et al. Prospective, observational study of voriconazole therapeutic drug monitoring among lung transplant recipients receiving prophylaxis: factors impacting levels of and associations between serum troughs, efficacy, and toxicity. Antimicrob Agents Chemother 2012, 56:2371-2377.
8. Park W.B., Kim N.H., Kim K.H., et al. The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial. Clin Infect Dis 2012, 55:1080-1087.
9. Andes D., Marchillo K., Stamstad T., Conklin R. In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model. Antimicrob Agents Chemother 2003, 47:3165-3169.
10. Han K., Capitano B., Bies R., et al. Bioavailability and population pharmacokinetics of voriconazole in lung transplant recipients. Antimicrob Agents Chemother 2010, 54:4424-4431.
11. Tan K., Brayshaw N., Tomaszewski K., Troke P., Wood N. Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities. J Clin Pharmacol 2006, 46:235-243.
12. Matsumoto K., Ikawa K., Abematsu K., et al. Correlation between voriconazole trough plasma concentration and hepatotoxicity in patients with different CYP2C19 genotypes. Int J Antimicrob Agents 2009, 34:91-94.
13. Brüggemann R.J., Donnelly J.P., Aarnoutse R.E., et al. Therapeutic drug monitoring of voriconazole. Ther Drug Monit 2008, 30:403-411.
14. Cockcroft D.W., Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron 1976, 16:31-41.
15. Kahle K., Langmann P., Schirmer D., et al. Simultaneous determination of voriconazole and posaconazole concentrations in human plasma by high-performance liquid chromatography. Antimicrob Agents Chemother 2009, 53:3140-3142.